Evidence map›Paper›PMID 33754251›Full record

ReviewMolecular biology reports2021

Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy.

Amit Gupta, Tapan Behl, Aayush Sehgal, Saurabh Bhatia, Dharmender Jaglan, Simona Bungau

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Unlocking the mechanistic potential ofJournal of traditional and complementary medicine · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Exploring the multifaceted role of TGF-β signaling in diabetic complications.Environmental science and pollution research international · 2022
    Review
  15. Review
  16. Review
  17. A spotlight on underlying the mechanism of AMPK in diabetes complications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Review
  18. Article
  19. Qihu Preparation Ameliorates Diabetes by Activating the AMPK Signaling Pathway in db/db Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Amit GuptaChitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India.
Tapan BehlChitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India. tapanbehl31@gmail.com.ORCID http://orcid.org/0000-0003-0993-7708
Aayush SehgalChitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India.
Saurabh BhatiaAmity Institute of Pharmacy, Amity University, Noida, Haryana, India.
Dharmender JaglanR.S. Memorial College of Pharmacy, Panipat, Haryana, India.
Simona BungauDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
Chitkara University · INAmity University · INUniversity of Oradea · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes (T2D) is one of the most widely spread metabolic disordersand is also referred as a 'lifestyle' disorder. According toa study conducted by IDB, the number of individuals affected with diabetes is expected to increase from 463 to 700 million by the end of year 2045. Thus, there is a great need to developed targeted therapies that can maintain homeostasis of glucose levels and improving insulin sensitivity which can overcome hurdles associated with conventional medicine. Detailed analysis was conducted by analyzing various research and review papers which were searched using MEDLINE and EMBASE using various keywords. This search retrieved the most appropriate content on these molecules targeting Nrf-2 functions and Nrf-2 pathway associated with diabetic neuropathy and nephropathy. In this review article, we have highlighted the role of Nrf-2 in diabetic associated complications of neuropathy and nephropathy. Since hyperglycemia is associated with oxidative stress and inflammation, regulating Nrf-2 activity through various synthetic and natural activators whichmay provide therapeutic benefits for the treatment and mitigation of diabetic neuropathy and nephropathy as well. Based on the available literature on Nrf-2 activity and despite some controversies in the association of Nrf-2 activity and its therapeutic usage, it can be concluded that regulation of this pathway is a trigger in the development of diabetes-associated complications. Thus, targeting this pathway with various activators may emerge as a novel therapy in the treatment of diabetes and diabetes-associated complications. Nrf-2 activation leading to regulation of various downstream pathways responsible for managament of Diabetic neuropathy and nephropathy Legend: Activities regulated by the activation of Nrf-2 pathway by Natural and Synthetic activators. Various downstream signalling pathway are involved in increase (+) and decrease (-) in levels of Nrf-2 levels. Subsequently controlling various mechanism involved in the pathogenies of Diabetic neuropathy and nephropathy.

Indexed as

Molecular Targeted TherapySignal TransductionAnimalsDiabetic NephropathiesDiabetic NeuropathiesHumansNF-E2-Related Factor 2NF-E2-Related Factor 2Diabetic nephropathyDiabetic neuropathyNrf-2 activationNrf-2 activatorsNrf-2-Keap-1 associationType-2 diabetes

Identifiers

PMID33754251
OpenAlexW3137868100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.